blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1735338

EP1735338 - ANTHRAX ANTIGENS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.02.2014
Database last updated on 15.07.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
Takeda Vaccines (Montana), Inc.
2155 Analysis Drive
Bozeman, MT 59718-6831 / US
[2013/25]
Former [2006/52]For all designated states
Ligocyte Pharmaceuticals, Inc.
2155 Analysis Drive
Bozeman, MT 59718-6831 / US
Inventor(s)01 / WIMER-MACKIN, Susan
609 Fieldstone Drive
Bozeman, MT 59715 / US
 [2006/52]
Representative(s)Lipscombe, Martin John, et al
Nash Matthews LLP
24 Hills Road
Cambridge CB2 1JP / GB
[N/P]
Former [2013/17]Lipscombe, Martin John, et al
Nash Matthews 90-92 Regent Street
Cambridge CB2 1DP / GB
Former [2006/52]Lipscombe, Martin John, et al
Keith W Nash & Co, 90-92 Regent Street
Cambridge CB2 1DP / GB
Application number, filing date05758632.311.02.2005
[2006/52]
WO2005US04678
Priority number, dateUS20040544130P11.02.2004         Original published format: US 544130 P
US20040544848P12.02.2004         Original published format: US 544848 P
[2006/52]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005086637
Date:22.09.2005
Language:EN
[2005/38]
Type: A2 Application without search report 
No.:EP1735338
Date:27.12.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 22.09.2005 takes the place of the publication of the European patent application.
[2006/52]
Type: B1 Patent specification 
No.:EP1735338
Date:24.04.2013
Language:EN
[2013/17]
Search report(s)International search report - published on:US28.12.2006
(Supplementary) European search report - dispatched on:EP14.03.2008
ClassificationIPC:A61K39/395, C07H21/00, A61K39/00, C07H21/02, A61K39/07, C12N9/54, C07H19/00, C12P21/04
[2007/07]
CPC:
A61K39/07 (EP,US); A61K2039/541 (EP,US); A61K2039/543 (EP,US);
A61K2039/55572 (EP,US); A61K2039/55583 (EP,US); A61K2039/55594 (EP,US)
Former IPC [2006/52]C07K14/16
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/52]
TitleGerman:ANTHRAX-ANTIGENE UND ANWENDUNGSVERFAHREN[2006/52]
English:ANTHRAX ANTIGENS AND METHODS OF USE[2006/52]
French:ANTIGENES DE L'ANTHRAX ET SES METHODES D'UTILISATION[2006/52]
Entry into regional phase08.11.2006National basic fee paid 
08.11.2006Search fee paid 
08.11.2006Designation fee(s) paid 
08.11.2006Examination fee paid 
Examination procedure08.11.2006Examination requested  [2006/52]
16.06.2008Amendment by applicant (claims and/or description)
28.01.2009Despatch of a communication from the examining division (Time limit: M06)
15.09.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
13.11.2009Reply to a communication from the examining division
13.04.2011Despatch of a communication from the examining division (Time limit: M06)
24.08.2011Reply to a communication from the examining division
12.06.2012Cancellation of oral proceeding that was planned for 27.06.2012
27.06.2012Date of oral proceedings (cancelled)
03.09.2012Communication of intention to grant the patent
03.01.2013Fee for grant paid
03.01.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.01.2009
Opposition(s)27.01.2014No opposition filed within time limit [2014/14]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.11.2009Request for further processing filed
13.11.2009Full payment received (date of receipt of payment)
Request granted
27.11.2009Decision despatched
Fees paidRenewal fee
27.02.2007Renewal fee patent year 03
13.02.2008Renewal fee patent year 04
13.02.2009Renewal fee patent year 05
16.02.2010Renewal fee patent year 06
15.02.2011Renewal fee patent year 07
15.02.2012Renewal fee patent year 08
12.02.2013Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.02.2005
AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
TR24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
[2016/33]
Former [2016/32]HU11.02.2005
AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/44]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
MC24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/14]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
NL24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/11]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
PL24.04.2013
RO24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/10]AT24.04.2013
BE24.04.2013
CY24.04.2013
CZ24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
SK24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2014/09]AT24.04.2013
BE24.04.2013
CY24.04.2013
DK24.04.2013
EE24.04.2013
FI24.04.2013
LT24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/52]AT24.04.2013
BE24.04.2013
CY24.04.2013
FI24.04.2013
LT24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/50]AT24.04.2013
BE24.04.2013
FI24.04.2013
LT24.04.2013
PL24.04.2013
SE24.04.2013
SI24.04.2013
BG24.07.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/49]AT24.04.2013
BE24.04.2013
FI24.04.2013
LT24.04.2013
SE24.04.2013
SI24.04.2013
GR25.07.2013
IS24.08.2013
PT26.08.2013
Former [2013/48]AT24.04.2013
LT24.04.2013
IS24.08.2013
PT26.08.2013
Former [2013/47]LT24.04.2013
PT26.08.2013
Documents cited:Search[A]WO0119395  (PASTEUR INSTITUT [FR], et al) [A] 1-48* the whole document *;
 [A]WO0145639  (UNIV OHIO STATE RES FOUND [US], et al) [A] 1-48 * the whole document *;
 [X]WO03037370  (MICROBIOLOGICAL RES AUTHORITY [GB], et al) [X] 1-48 * the whole document *;
 [X]  - IVINS B ET AL, "Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs.", VACCINE DEC 1995, (199512), vol. 13, no. 18, ISSN 0264-410X, pages 1779 - 1784, XP000579732 [X] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1016/0264-410X(95)00139-R
 [X]  - RHIE GI-EUN ET AL, "A dually active anthrax vaccine that confers protection against both bacilli and toxins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 16 SEP 2003, (20030916), vol. 100, no. 19, ISSN 0027-8424, pages 10925 - 10930, XP002306076 [X] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1834478100
 [X]  - IVINS B E ET AL, "Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.", INFECTION AND IMMUNITY FEB 1992, (199202), vol. 60, no. 2, ISSN 0019-9567, pages 662 - 668, XP009039710 [X] 1-48 * the whole document *
 [X]  - IVINS B E ET AL, "Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.", VACCINE JUL 1998, (199807), vol. 16, no. 11-12, ISSN 0264-410X, pages 1141 - 1148, XP004124617 [X] 1-48 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0264-410X(98)80112-6
International search[X]US6979449  (MOCK MICHELE [FR]);
 [Y]US6387665  (IVINS BRUCE [US], et al)
ExaminationWO02055133
    - FLICK-SMITH H.C. ET AL, "MUCOSAL OR PARENTERAL ADMINISTRATION OF MICROSPHERE-ASSOCIATED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN PROTECTS AGAINST ANTHRAX INFECTION IN MICE", INFECTION AND IMMUNITY, WASHINGTON, USA, (20020401), vol. 70, no. 4, pages 2022 - 20228, XP002977234

DOI:   http://dx.doi.org/10.1128/IAI.70.4.2022-2028.2002
    - SCHNEERSON RACHEL; ET AL, "Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: A potential addition to the anthrax vaccine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, WASHINGTON, DC.; US, (20030722), vol. 100, no. 15, pages 8945 - 8950, XP002306072

DOI:   http://dx.doi.org/10.1073/pnas.1633512100
    - VAN DER LUBBEN; ET AL, "Chitosan for mucosal vaccination", ADVANCED DRUG DELIVERY REVIEWS, (2001), vol. 52, page 139, XP002207356

DOI:   http://dx.doi.org/10.1016/S0169-409X(01)00197-1
    - KLAS S.D. ET AL, "A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge", VACCINE, (20080109), vol. 26, no. 43, pages 5494 - 5502
    - HUANG J ET AL, "A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats", VACCINE, ELSEVIER LTD, GB, (20040812), vol. 23, no. 6, doi:10.1016/J.VACCINE.2004.06.049, ISSN 0264-410X, pages 794 - 801, XP004637086

DOI:   http://dx.doi.org/10.1016/j.vaccine.2004.06.049
by applicant   - DEMICHELI ET AL., VACCINE, (1998), vol. 16, pages 880 - 884
    - FRIEDLANDER., J. APPL. MICROBIOL., (1999), vol. 87, page 303
    - HAMBLETON ET AL., VACCINE, (1984), vol. 2, pages 125 - 132
    - JERNIGAN ET AL., EMERG. INFECT. DIS., (2001), vol. 7, pages 933 - 944
    - OKINAKA ET AL., "Sequence and organization ofpXOl, the large Bacillus anthracis plasniid harboring the anthrax toxin genes", J. BACTERIOL., (1999), vol. 181, no. 20, pages 6509 - 6515
    - OKINAKA ET AL., "Sequence, assembly and analysis of pX01 and pX02", J. APPL. MICROBIOL., (1999), vol. 87, no. 2, pages 261 - 262
    - IVINS ET AL., VACCINE, (1995), vol. 13, no. 18, pages 1779 - 1784
    - Fundamental Immunology, LIPPINCOTT WILLIAMS & WILKINS, (2003), pages 1 - 1701
    - Fundamental Immunology, LIPPINCOTT WILLIAMS & WILLDNS, (2003), pages 1 - 1701
    - Goodman and Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (2001), pages 1463 - 1486
    - Fundamental Immunology, LIPPINCOTT WILLIAMS & WILLDNS, (2003), pages 497 - 523,561-
    - ROITT ET AL., Immunology, GOWER MEDICAL PUBLISHING, (1989), pages 1.1 - 1.10,2.8
    - Fundamental Immunology, LIPPINCOTT WILLIAMS & WILLDNS, (2003), pages 497 - 518
    - ROITT ET AL., Immunology, GOWER MEDICAL PUBLISHING, (1989), pages 1.1 - 1.10
    - Fundamental Immunology, LIPPINCOTT WILLIAMS & WILKINS, (2003), pages 512 - 513
    - SIMON ET AL., PNAS USA, (1992), vol. 89, no. 20, page 9367
    - HEST ET AL., FEBS LETT., (1998), vol. 428, no. 1-2, pages 68 - 70
    - TANG ET AL., ABSTR. PAP. AM. CHEM., page 218
    - T.E. CREIGHTON, Proteins: Structure and Molecular Properties, W.H. FREEMAN & CO., (1983), pages 79 - 86
    - FIELD ET AL., MOL. CELL. BIOL., (1988), vol. 8, pages 2159 - 2165
    - EVAN ET AL., MOLECULAR AND CELLULAR BIOLOGY, (1985), vol. 5, pages 3610 - 3616
    - PABORSKY, PROTEIN ENGINEERING, (1990), vol. 3, no. 6, pages 547 - 553
    - HOPP ET AL., BIOTECHNOLOGY, (1988), vol. 6, pages 1204 - 1210
    - MARTIN ET AL., SCIENCE, (1992), vol. 255, pages 192 - 194
    - SKINNER ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 15163 - 15166
    - LUTZ-FREYERMUTH ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 6393 - 6397
    - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 2444
    - DEVEREUX ET AL., NUCL. ACID RES., (1984), vol. 12, pages 387 - 395
    - "Current Methods in Sequence Comparison and Analysis", Macromolecule Sequencing and Synthesis, Selected Methods and Applications, ALAN R. LISS, INC., (1988), pages 127 - 149
    - FENG; DOOLITTLE, J. MOL. EVOL., (1987), vol. 35, pages 351 - 360
    - HIGGINS; SHARP, CABIOS, (1989), vol. 5, pages 151 - 153
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - KARLIN ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 5873 - 5787
    - ALTSCHUL ET AL., METHODS IN ENZYMOLOGY, (1996), vol. 266, pages 460 - 480
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, pages 3389 - 3402
    - "Controlled release ofbioactive agents from lactide/glycolide polymer", LEWIS, Biodegradable Polymers as Drug Delivery Systems, MARCEL DEKKER, (1990), pages 1 - 41
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.